J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, K. T.
Right arrow Articles by Kunka, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, K. T.
Right arrow Articles by Kunka, R. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS

Systemic Exposure and Urinary Cortisol Effects of Fluticasone Propionate Formulated With Hydrofluoroalkane in 4- to 11-Year-Olds With Asthma

Kenneth T. Kim, MD, Henry Milgrom, MD, Y. Kellie Yoon, MD, Arden L. Levy, MD, Paul Matz, MD, Michael J. Welch, MD, Anthony Cahn, MD, David A. Collins, PhD, Steven Kathman, PhD, Rashmi Mehta, PhD, Sheng-Fang Su, PhD and Robert L. Kunka, PhD

From the West Coast Clinical Trials, LLC, Cypress, California (Drs Kim, Yoon); National Jewish Medical and Research Centers, Denver, Colorado (Dr Milgrom); Spartanburg Pharmaceutical Research, Spartanburg, South Carolina (Dr Levy); Medford Medical Clinic, Medford, Oregon (Dr Matz); Allergy and Asthma Medical Group and Research Center, San Diego, California (Dr Welch); GlaxoSmithKline, Greenford, United Kingdom (Dr Cahn); GlaxoSmithKline, Research Triangle Park, North Carolina (Drs Collins, Kathman, Mehta, Kunka); and GlaxoSmithKline, Philadelphia, Pennsylvania (Dr Su). Presented in part at the annual meeting of the American College of Clinical Pharmacology, October 24-27, 2004, Dallas, Texas.

The systemic exposure of fluticasone propionate with hydrofluoroalkane propellant compared with chlorofluoro-carbon propellant and the effect of fluticasone propionate hydrofluoroalkane on 24-hour urinary cortisol in children aged 4 to 11 years with asthma were evaluated. Study 1 was an open-label, 2-way crossover study in which 16 subjects were randomized to 7.5 days each of fluticasone propionate hydrofluoroalkane 88 µg twice a day or fluticasone propionate chlorofluorocarbon 88 µg twice a day. In study 2, 63 subjects received 13.5 days of placebo followed by 27.5 days of fluticasone propionate hydrofluoroalkane 88 µg twice a day. The main outcome measure for study 1 was the difference between fluticasone propionate hydrofluoroalkane and fluticasone propionate chlorofluorocarbon in fluticasone propionate AUClast (area under the plasma fluticasone propionate concentration–time curve from zero up to the last quantifiable plasma concentration), and for study 2, 24-hour overnight urinary cortisol excretion. In study 1, fluticasone propionate systemic exposure was significantly lower (55%) with hydrofluoroalkane metered dose inhaler compared with chlorofluorocarbon metered dose inhaler. Study 2 showed no statistically significant changes in 24-hour overnight urinary cortisol excretion and no relationship to fluticasone propionate systemic exposure at this dose. The results of these 2 studies showed that in children aged 4 to 11 years with asthma, fluticasone propionate hydrofluoroalkane has lower systemic exposure compared with chlorofluorocarbon and no hypothalamic–pituitary–adrenal axis effects as measured by 24-hour urinary cortisol excretion.

Key Words: Children • asthma • fluticasone • systemic effects • urinary cortisol

Address for reprints: Kenneth T. Kim, MD, West Coast Clinical Trials, LLC, 5630 Cerritos Ave, Cypress, CA 90630.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Clinical Pharmacology